Search

Your search keyword '"PUVA therapy"' showing total 6,225 results
Start Over Descriptor "PUVA therapy"
6,225 results on '"PUVA therapy"'

51. Fototerapia como Primeira Linha Terapêutica para a Micose Fungóide: Um Estudo Retrospetivo de 10 Anos.

Author

Azevedo, Alexandra, Fernandes, Iolanda, Cabral, Renata, Lima, Margarida, Amorim, Isabel, and Selores, Manuela

Subjects
*PROGRESSION-free survival, *MYCOSIS fungoides, *PHOTOSENSITIZERS, *PHOTOTHERAPY
Abstract

Introduction: Phototherapy, particularly psoralen plus ultraviolet A (PUVA) and narrowband ultraviolet B (nbUVB), is a mainstay in the treatment of Mycosis Fungoides (MF). Methods: We analyzed outcomes of MF patients treated for the first time with either PUVA or nbUVB at the Photodermatology Unit, in the Department of Dermatology of Centro Hospitalar Universitário do Porto, from 2007 to 2017. The primary outcome was response to treatment. The secondary outcome was disease relapse free survival. Results: From a total number of 34 patients with MF identified, nine (26.5%) patients were diagnosed at stage IA and 25 (73.5%) patients were diagnosed at stage IB. Of these patients, 30 (88.2%) were treated with PUVA and four (11.8%) with nbUVB. Overall, 24 (80%) patients treated with PUVA and two (50%) patients treated with nbUVB had complete responses (CR). Relapse was observed in 17 (70.8%) PUVA treated patients and two (100%) nbUVB treated patients. Median disease relapse free survival was 12 months for PUVA and 6 months for nbUVB. Conclusion: PUVA is an effective therapy in early MF. Narrowband UVB could be a valid therapeutic alternative for these patients. However, the small size of nbUVB group in our study limits the conclusions about its efficacy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

52. Fotoquimioterapia e Fototerapia Ultravioleta B de Banda Estreita como Resgate de Terapêutica Biológica em Falência Secundária: Um Estudo Coorte Retrospetivo.

Author

B., Duarte, V., Serrão, Páris F., Rocha, Pinto G., Marques, M., Apetato, and J., Cabete

Subjects
*MELANOMA, *PHOTOSENSITIZERS, *PHOTOTHERAPY, *ADALIMUMAB, *BIOLOGICALS
Abstract

Introduction: Biologic drug survival in psoriasis is mainly limited by a decrease of effectiveness over time. Strategies to improve retention rates are needed. Our purpose was to evaluate the efficacy and tolerability of concurrent narrowband ultraviolet- B (NB-UVB) or photochemotherapy (PUVA) to salvage the biologic drug in secondary non-response. Methods: Retrospective cohort study of 18 adults with moderate-to-severe plaque psoriasis treated with biologics who received concurrent phototherapy after a secondary efficacy loss. Results: Twelve patients underwent PUVA concurrently with etanercept and adalimumab in 13 and 5 cycles, respectively. Clinical response was observed in 72.2% of cycles (PASI75 55.5%). Median PASI decreased by 73%. Sustained response was observed for 25 months (median). A malignant melanoma was identified during follow-up. Six patients underwent NB-UVB concurrently with etanercept, adalimumab and ustekinumab in 7.3 and 2 cycles, respectively. Clinical response was observed in 75% of cycles (PASI75 41.7%). Median PASI decreased by 80%. Sustained responde was observed for 21 months (median). Conclusions: This study adds real-life evidence that PUVA and NB-UVB are effective options to salvage and improve the long-term performance of biologic drugs. Further efficacy and safety data, especially addressing the skin malignancy risk, should be sought to clarify the role of this interesting approach in the modern era of improved biologic therapies. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

53. Researcher at University of Alabama at Birmingham Reports Research in Health and Medicine (Extracorporeal Photopheresis in Dermatological Diseases).

Abstract

A recent report from the University of Alabama at Birmingham discusses the use of extracorporeal photopheresis (ECP) in the treatment of dermatological diseases. ECP is a procedure commonly used for T-cell lymphoma, but it has also been tested for autoimmune conditions, including dermatologic diseases. The research highlights the potential of ECP to modify leukocytes and alter cytokine production, but notes that more evidence is needed to determine its efficacy in treating these dermatologic diseases. The report provides a review of the literature on ECP and discusses its applications, guidelines, recommendations, and future implementation for dermatologic diseases. [Extracted from the article]

Published
2024

54. Researchers from University Medical Center Hamburg-Eppendorf Report Recent Findings in Hepatitis (Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and...).

Abstract

Researchers from the University Medical Center Hamburg-Eppendorf have reported on successful treatment for refractory checkpoint inhibitor-induced hepatitis. Immune checkpoint inhibitors have been effective in treating malignant melanoma, but they can also lead to immune-related adverse events such as hepatitis. In this case, a 39-year-old woman with metastatic melanoma was successfully treated with a combination therapy consisting of prednisolone, mycophenolate-mofetil, extracorporeal photopheresis, and infliximab. This research provides valuable insights into the treatment of immune-mediated hepatitis caused by checkpoint inhibitors. [Extracted from the article]

Published
2024

55. New Findings Reported from Fred Hutchinson Cancer Research Center Describe Advances in Drug Research (Real-world Evidence of Heparin and Citrate Use In Extracorporeal Photopheresis: a Hypothesis-generating Data Review of Device Settings and...).

Abstract

A new report from the Fred Hutchinson Cancer Research Center in Seattle discusses the use of extracorporeal photopheresis (ECP) for the treatment of various immune-related conditions. The study compares the use of heparin and acid citrate dextrose-A (ACDA) as anticoagulants during ECP treatment. The research found that overall, the ECP system performed similarly with both anticoagulants, but ACDA showed potential benefits in reducing variability in photoactivation time. The study was supported by Mallinckrodt Pharmaceuticals and has been peer-reviewed. [Extracted from the article]

Published
2024

56. Findings from University of Lausanne in Cutaneous T-Cell Lymphoma Reported (Boost of Innate Immunity Cytokines As Biomarkers of Response To Extracorporeal Photopheresis In Patients With Leukaemic Cutaneous T-cell Lymphoma).

Abstract

A recent report from the University of Lausanne in Switzerland discusses the use of extracorporeal photopheresis (ECP) as a first-line immunomodulatory therapy for leukaemic cutaneous T-cell lymphoma (L-CTCL). The study aimed to investigate the effects of ECP on cytokine secretion patterns in patients with L-CTCL to better understand its mechanism of action. The researchers found that ECP stimulates the innate immune network and facilitates a boost in relevant innate immune cytokines, which can be used as biomarkers of response to ECP in patients with L-CTCL. This research provides valuable insights into the potential benefits of ECP in treating L-CTCL. [Extracted from the article]

Published
2024

57. University Clinic Researcher Yields New Findings on Cell Therapy (Extracorporeal photopheresis as a promising strategy for the treatment of GvHD after CAR-T cell therapy).

Abstract

Researchers from the University Clinic in Heidelberg, Germany have found that extracorporeal photopheresis (ECP) shows promise in treating graft-versus-host disease (GvHD) after CAR-T cell therapy. GvHD occurs in a significant number of patients receiving CAR-T cells after stem cell transplantation. ECP was found to reduce the alloreactivity of CAR-T cells without compromising their functionality. This research suggests that ECP could be a promising treatment strategy for GvHD after CAR-T cell therapy. [Extracted from the article]

Published
2024

58. Patent Issued for Systems and methods for photoactivation of a biological fluid (USPTO 11883543).

Subjects
PHOTOACTIVATION, GRAFT versus host disease
Abstract

A patent has been issued to Fenwal Inc. for systems and methods for photoactivation of a biological fluid. The patent describes an irradiation device that can be used in the treatment of blood products, such as red blood cells and white blood cells, with a photochemical agent activated by light. The device includes multiple light sources, light energy sensors, and a programmable controller to deliver a targeted light dose. The invention addresses the challenge of accounting for light-attenuating cellular material and variations in light intensity during treatment. This patent provides valuable information for researchers interested in the development of improved methods for extracorporeal photopheresis procedures. [Extracted from the article]

Published
2024

59. Studies from University Medical Center Mannheim Describe New Findings in Cutaneous T-Cell Lymphoma (Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma).

Abstract

A study conducted at the University Medical Center Mannheim in Germany has found that a combination therapy of mogamulizumab and extracorporeal photopheresis (ECP) is an effective treatment for erythrodermic cutaneous T-cell lymphoma (CTCL). The study included 11 patients with CTCL who received this combination therapy, and it resulted in an overall response rate of 73% in the skin and 64% in the blood. The therapy was well-tolerated, with common adverse events including mogamulizumab-associated rash, anemia, lymphocytopenia, and infusion-related reactions. This research provides new treatment options for CTCL patients and highlights the importance of combination therapies in managing this rare lymphoproliferative malignancy. [Extracted from the article]

Published
2024

60. Researcher from Johns Hopkins University Details New Studies and Findings in the Area of Cutaneous T-Cell Lymphoma (Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous...).

Abstract

A recent study conducted by researchers at Johns Hopkins University explores the use of mogamulizumab, a monoclonal antibody, in combination with other therapies for the treatment of cutaneous T-cell lymphoma (CTCL). The study found that the combination therapy resulted in positive treatment responses and durable outcomes for patients, with minimal adverse effects. The researchers suggest that this multimodality approach warrants further investigation and confirmation. This information may be valuable for individuals researching CTCL and seeking alternative treatment options. [Extracted from the article]

Published
2024

61. Studies from Newcastle University in the Area of Drug Research Reported (Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction).

Subjects
LYMPHOCYTES, HOMOGRAFTS, LUNG transplantation, MONONUCLEAR leukocytes, LUNGS
Abstract

A report from Newcastle University in the United Kingdom discusses the need for effective treatments for chronic lung rejection, also known as chronic lung allograft dysfunction (CLAD), following lung transplantation. The report evaluates the use and efficacy of lymphocyte depleting and immunomodulating therapies in progressive CLAD, including anti-thymocyte globulin, alemtuzumab, methotrexate, cyclophosphamide, total lymphoid irradiation, and extracorporeal photopheresis. The researchers suggest that extracorporeal photopheresis, anti-thymocyte globulin, and total lymphoid irradiation are currently the most viable second-line treatment options for progressive CLAD patients. However, the lack of randomized controlled trials limits the interpretation of the results. [Extracted from the article]

Published
2024

62. Photomedicine

Author

Kuimova, Marina K., Phillips, David, Evans, Rachel C., editor, Douglas, Peter, editor, and Burrow, Hugh D., editor

Published
2013
Full Text
View/download PDF

63. A Perspective on the Use of NB-UVB Phototherapy vs. PUVA Photochemotherapy

Author

Sally H. Ibbotson

Subjects
UVB, PUVA therapy, phototherapy, skin diseases, psoriasis, eczema, Medicine (General), R5-920
Abstract

Narrowband UVB (NB-UVB) phototherapy and psoralen-UVA (PUVA) photochemotherapy are widely used phototherapeutic modalities for a range of skin diseases. The main indication for NB-UVB and PUVA therapies is psoriasis, and other key diagnoses include atopic eczema, vitiligo, cutaneous T-cell lymphoma (CTCL), and the photodermatoses. The decision on choice of phototherapy is important and NB-UVB is usually the primary choice. NB-UVB phototherapy is a safe and effective therapy which is usually considered when topical agents have failed. PUVA requires prior psoralen sensitization but remains a highly effective mainstay therapy, often used when NB-UVB fails, there is rapid relapse following NB-UVB or in specific indications, such as pustular or erythrodermic psoriasis. This review will provide a perspective on the main indications for use of NB-UVB and PUVA therapies and provide comparative information on these important dermatological treatments.

Published
2018
Full Text
View/download PDF

65. Phototherapy

Author

Breuer, Kristine, Werfel, Thomas, Rustemeyer, Thomas, editor, Elsner, Peter, editor, John, Swen-Malte, editor, and Maibach, Howard I., editor

Published
2012
Full Text
View/download PDF

67. Evaluation of 25 years of phototherapy for treating psoriasis at a teaching hospital in southern Spain

Author

Tomas Toledo-Pastrana, María José García-Hernández, Ana María Carrizosa-Esquivel, and Francisco Miguel Camacho-Martínez

Subjects
Epidemiology, PUVA Therapy, Photobiology, Psoriasis, Time-to-Treatment, Dermatology, RL1-803
Abstract

AbstractBACKGROUND:For years, phototherapy has been used in a wide range of skin diseases, which is unsurprising as skin is the anatomical feature most directly exposed to light, especially in psoriasis. Although the role of light therapy has been replaced by different therapeutic modalities in recent years, this treatment is now an established option for many skin diseases.OBJECTIVES:The aim was to characterize the patient population thathad received the aforementioned treatment in the Virgen Macarena Health Area in Seville (Spain) between June 1985 and October 2011.METHODS:We have designed a descriptive study with a univariate analysis covering 443 treatments with light therapy, all administered to the same number of patients suffering from psoriasis.RESULTS:79.15% of patients were discharged due to improvement or healing, while the 20.85% were discharged due to other reasons. The average total accumulative dose was 131.53 J/cm2. We do not detected an increase in proportion in patients for develop NMSK after light therapy treatment.CONCLUSIONS:We consider that phototherapy is still an effective and efficient treatment that will have to be reconsidered in the current macroeconomic context.

Published
2015
Full Text
View/download PDF

68. Phototherapy as an effective treatment for Majocchi's disease - Case report

Author

Tapan Kumar Dhali, Monica Chahar, and Mohammad Asad Haroon

Subjects
PUVA therapy, Phototherapy, Pigmentation disorders, Dermatology, RL1-803
Abstract

Pigmented purpuric dermatoses are chronic and relapsing disorders characterized by a symmetrical rash of petechial and pigmentary macules, mainly confined to the lower limbs. Purpura annularis telangiectodes of Majocchi is a less common variant of Pigmented purpuric dermatoses characterized by punctate telangiectatic macules progressing to annular, hyperpigmented patches with central clearing and infrequent atrophy. A 12 year-old girl presented with asymptomatic round to oval reddish brown macules, present symmetrically over her lower and upper limbs for 3 years. Few lesions were annular in shape. Biopsy from the lesion was compatible with Pigmented purpuric dermatoses. On the basis of clinical and histopathological findings, a diagnosis of Purpura annularis telangiectodes of Majocchi was made. The patient began phototherapy thrice a week and showed excellent response.

Published
2015
Full Text
View/download PDF

69. Bath-psoralen plus UVA therapy changes inflammatory proteomic signatures for systemic effects beyond the skin.

Author

Kanayama Y, Ikumi K, Sakurai M, Enomoto Y, Nishida E, Yamamoto A, and Morita A

Subjects
Proteomics, Skin, PUVA Therapy, Methoxsalen, Ficusin, Ultraviolet Therapy
Abstract

Competing Interests: Conflict of Interest A.M. has received research grants, consulting fees, and/or speaker’s fees from AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Eisai, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, NichiIko Pharmaceutical, Nippon Kayaku, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and Ushio. The remaining authors state no conflict of interest.

Published
2023
Full Text
View/download PDF

71. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin.

Author

Olafsson S, Rodriguez E, Lawson ARJ, Abascal F, Huber AR, Suembuel M, Jones PH, Gerdes S, Martincorena I, Weidinger S, Campbell PJ, and Anderson CA

Subjects
Humans, Ficusin therapeutic use, PUVA Therapy, Mutation, Psoriasis drug therapy, Psoriasis genetics, Psoriasis pathology, Furocoumarins therapeutic use
Abstract

Somatic mutations are hypothesized to play a role in many non-neoplastic diseases. We performed whole-exome sequencing of 1,182 microbiopsies dissected from lesional and nonlesional epidermis from 111 patients with psoriasis to search for evidence that somatic mutations in keratinocytes may influence the disease process. Lesional skin remained highly polyclonal, showing no evidence of large-scale spread of clones carrying potentially pathogenic mutations. The mutation rate of keratinocytes was similarly only modestly affected by the disease. We found evidence of positive selection in previously reported driver genes NOTCH1, NOTCH2, TP53, FAT1 and PPM1D and also identified mutations in four genes (GXYLT1, CHEK2, ZFP36L2 and EEF1A1) that we hypothesize are selected for in squamous epithelium irrespective of disease status. Finally, we describe a mutational signature of psoralens-a class of chemicals previously found in some sunscreens and which are used as part of PUVA (psoralens and ultraviolet-A) photochemotherapy treatment for psoriasis., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

72. Vitiligo

Author

Bahadoran, Philippe, Ortonne, Jean-Paul, Krieg, Thomas, editor, Bickers, David R., editor, and Miyachi, Yoshiki, editor

Published
2010
Full Text
View/download PDF

74. Psoriasis

Author

Iizuka, Hajime, Krieg, Thomas, editor, Bickers, David R., editor, and Miyachi, Yoshiki, editor

Published
2010
Full Text
View/download PDF

84. Juvenile localized scleroderma: clinical picture, diagnosis, therapeutic update (literature review and own observations)

Author

L.F. Bogmat and V.V. Nikonova

Subjects
medicine.medical_specialty, medicine.medical_treatment, review, Disease, Pediatrics, RJ1-570, Scleroderma, Lesion, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Immune system, children, Fibrosis, medicine, General Environmental Science, integumentary system, business.industry, medicine.disease, Dermatology, Tacrolimus, 030220 oncology & carcinogenesis, PUVA therapy, rheumatic diseases, juvenile localized scleroderma, General Earth and Planetary Sciences, Methotrexate, medicine.symptom, business, medicine.drug
Abstract

Among rheumatic diseases in children, a special place belongs to juvenile localized scleroderma, which is highlighted as a separate form in the structure of scleroderma diseases and is characterized by: the onset of the disease up to 16 years, skin lesions, often focal or linear (hemiforma), a tendency to form contractures and the development of limbs abnormalities. This form of the disease is characterized by damage to the skin mainly involving the surrounding muscles. The cause of juvenile localized scleroderma is unclear. Three main components underlie the development of the disease: damage to the vascular bed, activation of the immune system with a violation of its regulation and release of cytokines, as well as altered collagen synthesis with proliferation of fibroblasts and the subsequent development of fibrosis. Several forms of juvenile localized scleroderma have been identified, differing in clinical manifestations and depth of lesion of subjacent tissues, and among the skin manifestations, five subtypes are distinguished: plaque, generalized, linear, pansclerotic, and mixed. Diagnosis is based on an analysis of the history and typical clinical picture of the disease. Specific laboratory tests to confirm the disease has not been developed. Modern treatment principles for juvenile localized scleroderma involve the use of different groups of drugs, including methotrexate, corticosteroids, tacrolimus, cyclosporine, imatinibum, mycophenolate mofetil, retinoids, PUVA therapy (Psoralen + UltraViolet A), use of slow calcium channel antagonists (nifedipinum group), bosentan. The studies currently being conducted in the world on the standardization of basic therapy of juvenile localized scleroderma are likely to reveal the optimal variant and duration of treatment for each form of the disease and improve the prognosis of the disease. The article also presents the results of own clinical observations.

Published
2021
Full Text
View/download PDF

85. Effectiveness of narrowband UVB phototherapy and psoralen plus UVA photochemotherapy in the treatment of generalized lichen planus: Results from a large retrospective analysis and an update of the literature

Author

Benedikt Weber, Elias Marquart, Adrian Tanew, and Sonja Radakovic

Subjects
medicine.medical_specialty, medicine.medical_treatment, Immunology, Narrow band uvb, Dermatology, chemistry.chemical_compound, medicine, Retrospective analysis, Humans, Immunology and Allergy, Narrowband UVB phototherapy, Radiology, Nuclear Medicine and imaging, skin and connective tissue diseases, Adverse effect, PUVA Therapy, Bath puva, Psoralen, Retrospective Studies, Photosensitizing Agents, integumentary system, business.industry, Ficusin, Lichen Planus, Retrospective cohort study, General Medicine, Phototherapy, Treatment Outcome, Photochemotherapy, chemistry, PUVA therapy, Ultraviolet Therapy, business
Abstract

Background The aim of this retrospective study was to compare the efficacy and safety of different phototherapeutic modalities in the treatment of cutaneous lichen planus (LP). Methods We retrospectively analyzed the chart data of 53 patients with generalized LP who had been subjected to narrowband UVB (NB-UVB) or photochemotherapy (PUVA) between January 1997 and April 2020. Of these, 30 patients had received NB-UVB, 18 patients oral PUVA and 5 patients bath PUVA. Results Fifty patients completed a full treatment course. The percentage of patients with a complete (>90% clearing) or good (51%-90% clearing) response was similar for NB-UVB versus PUVA (86.2% vs. 90.5%; P = 1.00). The number of exposures required for obtaining a complete or good response was also comparable for both treatment groups (NB-UVB: 28.9 ± 12.3 vs. PUVA: 25.4 ± 10.1; P = .209). Adverse events, in particular gastrointestinal upsets, were recorded in 26.1% of patients treated with oral PUVA while none were observed with NB-UVB. Conclusion The therapeutic outcome and the number of treatments required for achieving a complete or good response were comparable for NB-UVB and PUVA; however, PUVA therapy was associated with a substantially higher rate of moderate adverse events.

Published
2021
Full Text
View/download PDF

86. Alitretinoin in the treatment of cutaneous T‐cell lymphoma

Author

Till Kaemmerer, Pia‐Charlotte Stadler, Leonie Helene Frommherz, Anne Guertler, Lars Einar French, and Markus Reinholz

Subjects
Adult, Male, Skin Neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, non‐Hodgkin's lymphoma, Antineoplastic Agents, Middle Aged, survival, Combined Modality Therapy, Lymphoma, T-Cell, Cutaneous, cancer management, drug discovery and delivery, Mycosis Fungoides, Clinical Cancer Researcher, Bexarotene, Disease Progression, Humans, Sezary Syndrome, Female, PUVA Therapy, RC254-282, Research Articles, Alitretinoin, Research Article, Aged
Abstract

Introduction In this survey, we analyzed data from patients suffering from the most common cutaneous T‐cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) and Sézary syndrome (SS), treated with the retinoid alitretinoin during a 7‐year period at our outpatient department between 2015 and 2020. Materials and Methods We analyzed patient medical records including TNMB stage, side effects under therapy with alitretinoin, time to next treatment (TTNT), and previous photo documentation. Results A total of 35 patients with MF (n = 28) and SS (n = 7) were included in the study, of whom 69% were male and 31% were female. The mean age of onset was 56 ± 15 years in MF and 65.4 ± 10.8 years in SS with 51.4% having early stage (IA–IIA) and 48.6% having advanced stage (IIB–IVA) CTCL. Of these patients 37.2% responded to alitretinoin, 28.6% had a stable course, and 34.3% experienced progression. Alitretinoin was administered as a monotherapy (25.7%) or combined with five concomitant therapies (74.2%), most frequently with ECP (31.4%) and PUVA (11.4%). 63% did not report any side effects, most often hypertriglyceridemia (20%) was described. Conclusion Considering that nearly two thirds of the CTCL patients treated with alitretinoin showed a response or stable disease, together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs. This survey represents the largest number of recorded therapies with the retinoid alitretinoin in CTCLs in a European patient collective., We analyzed data from patients suffering from the CTCL subtypes mycosis fungoides (MF) and Sézary syndrome (SS), treated with the retinoid alitretinoin during a 7‐year period at our outpatient department. Together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs.

Published
2021

87. Efficacy of bath‐psoralen and ultraviolet A therapy for mycosis fungoides – retrospective analysis of 62 cases

Author

Masuda Hideyuki, Akimichi Morita, Ryoji Kubo, Motoki Nakamura, Kyoko Ikumi, Shoichi Watanabe, Shinnosuke Muramatsu, Kazuhiko Matsumoto, Sayuri Yamazaki, Yoichi Shintani, Emi Nishida, and Takuya Furuhashi

Subjects
medicine.medical_specialty, Skin Neoplasms, Dermatology, Ultraviolet therapy, Gastroenterology, chemistry.chemical_compound, Mycosis Fungoides, Refractory, Internal medicine, medicine, Humans, Stage (cooking), PUVA Therapy, Psoralen, Retrospective Studies, Mycosis fungoides, business.industry, Hazard ratio, Ficusin, Retrospective cohort study, General Medicine, medicine.disease, Treatment Outcome, chemistry, Ultraviolet Therapy, business, Progressive disease
Abstract

Photochemotherapy with psoralen and ultraviolet A (PUVA) is widely used for refractory skin diseases. Bathwater delivery of 8-methoxypsoralen (8-MOPS) with subsequent UVA irradiation (bath-PUVA) or oral administration of 8-MOPS with UVA is used to treat mycosis fungoides. We retrospectively analyzed 62 patients with mycosis fungoides (8 stage IA, 30 stage IB, 5 stage IIB, 18 stage IIIA, and 1 stage IVA2) treated with bath-PUVA at the Dermatology Clinic of Nagoya City University Hospital from November 2004 to December 2013. A complete response was achieved in 37 (59.7%) patients, a partial response was achieved in 16 (25.8%), and stable disease was achieved in 6 (9.7%). Progressive disease was observed in 3 (4.8%) patients. Almost all patients in stage IA/IB achieved a complete response. Of the 5 stage IIB patients, 2 achieved a partial response, 1 achieved stable disease, and 2 had progressive disease. The serum concentrations of soluble interleukin-2 receptor and lactate dehydrogenase decreased significantly following treatment with bath-PUVA (p

Published
2021
Full Text
View/download PDF

88. Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD.

Abstract

This document provides information about a clinical trial that is not yet recruiting participants. The trial aims to evaluate the effectiveness of a treatment for acute graft-versus-host disease (GVHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation. The treatment involves a combination of extracorporeal photopheresis (ECP) and steroids. The trial will enroll 42 participants and is expected to be completed in January 2026. The eligibility criteria for participants are outlined, and the responsible party for the trial is the Central Hospital in Nancy, France. [Extracted from the article]

Published
2023

89. Studies from Tehran University of Medical Sciences Reveal New Findings on Nuclear Proteins (Evaluation of the Cellular Resistance Process in Treated Cells Via Extracorporeal Photopheresis).

Abstract

A recent study conducted by researchers at Tehran University of Medical Sciences in Iran explored the cellular resistance process in treated cells through extracorporeal photopheresis (ECP). ECP is a therapeutic method used for diseases such as cancers, particularly leukemic cutaneous T-cell lymphoma (CTCL). The researchers analyzed data from the Gene Expression Omnibus (GEO) database and identified 57 significant differentially expressed genes (DEGs) related to ECP treatment. They found that 15 histones from the H2A, H2B, and H3 families, especially the H2A family, played a crucial role in the resistance property of the treated cells. The study suggests that sensitivity to ECP treatment depends on molecular events involving histones. [Extracted from the article]

Published
2023

90. Reports from University Health Network Highlight Recent Findings in Graft-Versus-Host Disease [Single Centre Retrospective Analysis of Extracorporeal Photopheresis (Ecp) Therapy In Patients Heavily Pre-treated for Chronic Graft-versus-host...].

Abstract

Toronto, Canada, North and Central America, Graft-Versus-Host Disease, Health and Medicine, Immune System Diseases and Conditions, PUVA Therapy, Photopheresis, Phototherapy, Risk and Prevention, Transplantation Keywords: Toronto; Canada; North and Central America; Graft-Versus-Host Disease; Health and Medicine; Immune System Diseases and Conditions; PUVA Therapy; Photopheresis; Phototherapy; Risk and Prevention; Transplantation EN Toronto Canada North and Central America Graft-Versus-Host Disease Health and Medicine Immune System Diseases and Conditions PUVA Therapy Photopheresis Phototherapy Risk and Prevention Transplantation 426 426 1 11/06/23 20231109 NES 231109 2023 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Data detailed on Immune System Diseases and Conditions - Graft-Versus-Host Disease have been presented. [Extracted from the article]

Published
2023

91. The effect of UVA light/8-methoxypsoralen exposure used in Extracorporeal Photopheresis treatment on platelets and extracellular vesicles.

Subjects
EXTRACELLULAR vesicles, BLOOD platelets, PHOTOCHEMOTHERAPY, CUTANEOUS T-cell lymphoma, BLOOD platelet aggregation
Abstract

Extracorporeal Photopheresis (ECP) is a treatment for Cutaneous T-Cell Lymphoma that uses UVA light and a photoactivated drug called 8-methoxypsoralen. However, 25% of patients do not respond to this treatment, and the reasons for this are unknown. This study investigated the effects of UVA light and 8-methoxypsoralen on platelets and extracellular vesicles (EVs) in vitro. The researchers found that this treatment did not activate platelets or significantly alter levels of platelet activation markers or EVs. Further research is needed to confirm these findings in vivo. [Extracted from the article]

Published
2023

92. Reports Outline Drug Research Findings from Osaka University [Efficacy of a 365 Nm Ultraviolet A1 Light Emitting Diode (Uva1-led) In in Vitro Extracorporeal Photopheresis].

Abstract

The news correspondents obtained a quote from the research from Osaka University, "In recent years, the use of a light emitting diode (LED) in the clinic has attracted considerable interest. Keywords: Osaka; Japan; Asia; Drug Research; Cell Proliferation; Electronics; Health and Medicine; Light-emitting Diode; PUVA Therapy; Photopheresis; Phototherapy EN Osaka Japan Asia Drug Research Cell Proliferation Electronics Health and Medicine Light-emitting Diode PUVA Therapy Photopheresis Phototherapy 2192 2192 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Drug Research are discussed in a new report. [Extracted from the article]

Published
2023

93. Hospital de Pediatria JP Garrahan Reports Findings in Graft-Versus-Host Disease (Treatment of graft versus host disease with photopheresis interferes in voriconazole therapeutic drug monitoring: A case study).

Subjects
GRAFT versus host disease, DRUG monitoring, VORICONAZOLE, HEMATOPOIETIC stem cells, PHOTOCHEMOTHERAPY
Abstract

Keywords: Buenos Aires; Argentina; South America; Antifungals; Antiinfectives; Azole Antifungals; Bone Marrow Cells; Drugs and Therapies; Graft-Versus-Host Disease; Health and Medicine; Hematopoietic Stem Cells; Immune System Diseases and Conditions; PUVA Therapy; Pediatrics; Pharmaceuticals; Photopheresis; Phototherapy; Stem Cell Research; Voriconazole Therapy EN Buenos Aires Argentina South America Antifungals Antiinfectives Azole Antifungals Bone Marrow Cells Drugs and Therapies Graft-Versus-Host Disease Health and Medicine Hematopoietic Stem Cells Immune System Diseases and Conditions PUVA Therapy Pediatrics Pharmaceuticals Photopheresis Phototherapy Stem Cell Research Voriconazole Therapy 302 302 1 10/30/23 20231103 NES 231103 2023 NOV 4 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Immune System Diseases and Conditions - Graft-Versus-Host Disease is the subject of a report. For more information on this research see: Treatment of graft versus host disease with photopheresis interferes in voriconazole therapeutic drug monitoring: A case study. [Extracted from the article]

Published
2023

94. Findings from University of Pittsburgh Update Knowledge of Mycosis Fungoides (What Does the Future Hold for Biomarkers of Response To Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?).

Abstract

Findings from University of Pittsburgh Update Knowledge of Mycosis Fungoides (What Does the Future Hold for Biomarkers of Response To Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?) Keywords for this news article include: Pittsburgh, Pennsylvania, United States, North and Central America, Biomarkers, Cancer, Cutaneous Lymphoma, Dermatology, Diagnostics and Screening, Health and Medicine, Lymphoproliferative Diseases and Conditions, Lymphoproliferative Disorders, Mycosis Fungoides, Oncology, PUVA Therapy, Photopheresis, Phototherapy, T-Cell, University of Pittsburgh. Keywords: Pittsburgh; State:Pennsylvania; United States; North and Central America; Biomarkers; Cancer; Cutaneous Lymphoma; Dermatology; Diagnostics and Screening; Health and Medicine; Lymphoproliferative Diseases and Conditions; Lymphoproliferative Disorders; Mycosis Fungoides; Oncology; PUVA Therapy; Photopheresis; Phototherapy; T-Cell EN Pittsburgh State:Pennsylvania United States North and Central America Biomarkers Cancer Cutaneous Lymphoma Dermatology Diagnostics and Screening Health and Medicine Lymphoproliferative Diseases and Conditions Lymphoproliferative Disorders Mycosis Fungoides Oncology PUVA Therapy Photopheresis Phototherapy T-Cell 958 958 1 10/30/23 20231031 NES 231031 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in Lymphoproliferative Diseases and Conditions - Mycosis Fungoides. [Extracted from the article]

Published
2023

95. Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease.

Abstract

Keywords: Adrenal Cortical Steroids; Antineoplastics; Antirheumatics; Biomedicine; Biotechnology; Cell Transplantation; Cell Transplants; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Etanercept Therapy; Globulins; Glucocorticoids; Graft-Versus-Host Disease; Health and Medicine; Hormones; Immune System Diseases and Conditions; Immune System Diseases and Conditions - Graft-Versus-Host Disease; Immunologic Agents; Infliximab Therapy; Metabolism; Monoclonal Antibodies; PUVA Therapy; Pediatrics; Peptides and Proteins; Pharmaceuticals; Photopheresis; Phototherapy; Prednisone Therapy; Proteins; Quality of Life; Stem Cell Research; Surgery; Transplant Medicine; Tumor Necrosis Factor (TNF) Inhibitors; Wellness EN Adrenal Cortical Steroids Antineoplastics Antirheumatics Biomedicine Biotechnology Cell Transplantation Cell Transplants Clinical Research Clinical Trials and Studies Drugs and Therapies Etanercept Therapy Globulins Glucocorticoids Graft-Versus-Host Disease Health and Medicine Hormones Immune System Diseases and Conditions Immune System Diseases and Conditions - Graft-Versus-Host Disease Immunologic Agents Infliximab Therapy Metabolism Monoclonal Antibodies PUVA Therapy Pediatrics Peptides and Proteins Pharmaceuticals Photopheresis Phototherapy Prednisone Therapy Proteins Quality of Life Stem Cell Research Surgery Transplant Medicine Tumor Necrosis Factor (TNF) Inhibitors Wellness 468 468 1 10/24/23 20231024 NES 231024 2023 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Staff editors report on the newly launched clinical trial, NCT06075706, which has the following summary description: "The purpose of this trial is the comparative evaluation of overall response rate (ORR) in paediatric participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Visit Day 28 after treatment with MC0518 or first used best available therapy (BAT).". [Extracted from the article]

Published
2023

96. Researcher from University of Pittsburgh Reports Details of New Studies and Findings in the Area of Sezary Syndrome (What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sezary Syndrome?).

Abstract

Keywords: Biomarkers; Cancer; Cutaneous Lymphoma; Dermatology; Diagnostics and Screening; Health and Medicine; Immunoproliferative Disorders; Lymphatic Diseases and Conditions; Lymphoproliferative Diseases and Conditions; Lymphoproliferative Disorders; Mycosis Fungoides; Oncology; PUVA Therapy; Photopheresis; Phototherapy; Sezary Syndrome; T-Cell EN Biomarkers Cancer Cutaneous Lymphoma Dermatology Diagnostics and Screening Health and Medicine Immunoproliferative Disorders Lymphatic Diseases and Conditions Lymphoproliferative Diseases and Conditions Lymphoproliferative Disorders Mycosis Fungoides Oncology PUVA Therapy Photopheresis Phototherapy Sezary Syndrome T-Cell 2138 2138 1 10/09/23 20231010 NES 231010 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Sezary syndrome. Biomarkers, Cancer, Cutaneous Lymphoma, Dermatology, Diagnostics and Screening, Health and Medicine, Immunoproliferative Disorders, Lymphatic Diseases and Conditions, Lymphoproliferative Diseases and Conditions, Lymphoproliferative Disorders, Mycosis Fungoides, Oncology, PUVA Therapy, Phototherapy, Photopheresis, T-Cell, Sezary Syndrome. [Extracted from the article]

Published
2023

99. Circulating T regulatory cells in patients with psoriasis with and without atherosclerosis: A pilot comparative study before and after photochemotherapy

Author

Wedad Z. Mostafa, Esraa Fawzy Aly, Marwa F Hussein, Vanessa Hafez, Mervat M. Khorshied, Essam Baligh Eweis, Amir Mostafa Abdel Meged, and Marwa El-Hawary

Subjects
Duplex ultrasonography, medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunology, MEDLINE, Dermatology, General Medicine, Atherosclerosis, medicine.disease, Text mining, Photochemotherapy, Psoriasis, PUVA therapy, medicine, Humans, Methoxsalen, Immunology and Allergy, Ultraviolet Therapy, Radiology, Nuclear Medicine and imaging, In patient, business
Published
2021
Full Text
View/download PDF

100. Evaluation of serum folate level before and after oral PUVA therapy in psoriatic patients

Author

S.E. Ibrahim, R.T. Shafik, and A.A. Ibrahim

Subjects
Folic acid level, medicine.medical_specialty, Serum folate level, Erythema, business.industry, medicine.medical_treatment, General Medicine, Ultraviolet a, medicine.disease, Serum folate, Psoriasis, Internal medicine, PUVA therapy, medicine, medicine.symptom, Adverse effect, business
Abstract

Psoriasis is a chronic, recurrent, and immune-mediated inflammatory disease that affects 2–3% of the world population. The present study aimed to evaluate serum folate level before and after oral PUVA therapy in psoriatic patients. Patient and methods: A total of 40 psoriatic patients without any other morbidities (age ranged from 19 to 63 years, including 20 males and 20 females), All the patients recieved oral 8-methoxypsoralen at a dose of 0.6 mg/kg, followed 2 hours later by ultraviolet A exposure (oral PUVA therapy), For each patient the therapy will be twice weekly for eight weeks. Patients in the PUVA group were treated twice times weekly with a starting dose of 2 J/cm2, increasing by 20% each session, to a maximum of 15 J/cm2 per dose. Patients underwent up to 16 sessions. The dosage was adjusted if patients developed erythema. We have measured serum folate levels at baseline and after oral PUVA exposure. Also we use PASI score as objective method to visualize the relationship between improvement of psoriasis and changes in folate serum levels at baseline and after 16 exposures to PUVA for 8 weeks along with subjective methods which were done by photography and adverse effects were also reported. Results: There is statistically significant decrease of folic acid level after 16 sessions of phototherapy by average 20%. According to PASI score, Our results shows that there is statistically significant improvement in PASI score after phototherapy by average 60% .Conclusion: Folate deficiency should be evaluated and corrected in the patients, as it may be aggravated by UV therapy.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results